- Worldwide cannabis market expected to reach between $30 billion and $50 billion within four years
- Patent protected disruptive technology enables more efficient delivery and absorption of cannabinoids
- Groundbreaking delivery technology DehyraTECH™ positions Lexaria as potential M&A prospect
Lexaria BioScience Corp. (CSE: LXX) (OTCQB: LXRP), a Canadian biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, including cannabinoids, now has multiple patents pending in over 40 countries around the world. The company’s first patents, issued in the United States and Australia, relate to edible forms of cannabinoids or CBDs. Hot off a winning presentation at the 2017 Marijuana Business Conference & Expo (MJBizCon) in Las Vegas, Lexaria’s chairman and CEO Chris Bunka offered some thoughts on the future of cannabis during an interview with The Street at the LD Micro conference in Los Angeles last week.
“The market potential of cannabis is really exploding worldwide, it’s not just an American phenomenon, it’s happening in Canada, Mexico, Germany, Australia, all over the world,” Bunka told The Street’s Kinsey Grant (http://dtn.fm/8WNgf). “It’s expected to be in the $30-$50 billion range in the next three to four years … and growing very, very rapidly.”
Lexaria BioScience’ss groundbreaking technology is specifically created for the delivery of APIs, or active pharmaceutical ingredients, found in cannabis, vitamins, non-steroidal anti-inflammatory drugs and, even, nicotine.
“We effectively help CBDs get into the bloodstream more rapidly and more efficiently than they otherwise can,” Bunka told Grant in the interview. “We’ve developed this technology – we’re really a research and development company – and we license it off to other companies that have expertise in developing consumer products or cannabis-related products, and they utilize our technology to make those products better.”
The company’s DehydraTECH™ proprietary technology is not only cost effective, it has been proven to enhance the performance of beneficial compounds in ingestible products (http://dtn.fm/tWdB2). An edible cannabinoid product, for instance, becomes better tasting, better smelling, has better bioavailability and absorption, and lasts longer when Lexaria’s patented delivery technology is utilized. Because Lexaria’s technology enables or works with all ingested forms of cannabinoids, the company is seen as an attractive partner with various biotech companies conducting cannabinoid research and development, and it could be an equally attractive acquisition target (http://dtn.fm/Ur8Ya).
Lexaria research and development partnership with the Canadian government’s National Research Council underscores the significance of its unique technology. Results from the endeavor are expected to support accelerating B2B relationships – and not just in the booming cannabis and CBD/hemp oil industry. Much more can be done to enhance and enable delivery of active pharmaceutical ingredients in a wide variety of important health-related fields, offering Lexaria additional future growth potential.
For more information, visit the company’s website at www.LexariaEnergy.com
Let us hear your thoughts: Lexaria Bioscience Corp. Message Board
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.